The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ivanov M.V.

FGBU "Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva", Sankt-Peterburg

Zubov D.S.

Bekhterev National Medical Research Center of Psychiatry and Neurology, St.-Petersburg, Russia

Electroconvulsive therapy in treatment of resistant schizophrenia: biological markers of efficacy and safety

Authors:

Ivanov M.V., Zubov D.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(3): 92‑97

DOI: 10.17116/jnevro201911903192

Read: 15335 times

Contact the author
Table of contents

ELECTROCONVULSIVE THERAPY IN TREATMENT OF RESISTANT SCHIZOPHRENIA: BIOLOGICAL MARKERS OF EFFICACY AND SAFETY
ELECTROCONVULSIVE THERAPY IN TREATMENT OF RESISTANT SCHIZOPHRENIA: BIOLOGICAL MARKERS OF EFFICACY AND SAFETY

To cite this article:

Ivanov MV, Zubov DS. Electroconvulsive therapy in treatment of resistant schizophrenia: biological markers of efficacy and safety. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(3):92‑97. (In Russ.)
https://doi.org/10.17116/jnevro201911903192

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Study of neurodegeneration in multiple scle­rosis using opti­cal cohe­rence tomo­graphy of the retina and magnetic reso­nance morphometry of the brain. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):66-72
Targets of rational neuroprotection in the therapy of chro­nic cere­bral ischemia and the possibilities of achieving them. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):96-101
Resu­lts of the inte­rnational multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the effi­cacy and safety of the sequential therapy with ethy­lmethylhydroxypyridine succinate in patients in the acute and early reco­very periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53
Expe­rimental and clinical evaluation of the safety and effi­cacy of Poly­dexa spray with phenylephrine in acute rhinosinusitis. Russian Bulletin of Otorhinolaryngology. 2025;(4):39-46
The role of Inflasinusans in the treatment of acute rhinosinusitis. Russian Bulletin of Otorhinolaryngology. 2025;(4):64-71
Use of ozone therapy in the treatment of complications following pene­trating kera­toplasty for rosa­cea-associated kera­titis. Russian Annals of Ophthalmology. 2025;(4):66-72
Costs of home-based respiratory support and oxygen therapy. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):93-102
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
The use of grape poly­phenols in combination with magnetic therapy in patients with bronchial asthma who have suffered a new coro­navirus infe­ction. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(4):14-19
Resu­lts of manual therapy in dege­nerative spine diseases with and without radi­culopathy. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(4):47-55
Abstract:

Objective. To evaluate clinical and biological efficacy and safety of electroconvulsive therapy (ECT) in patients with treatment-resistant paranoid schizophrenia. Material and methods. Determination of CNS specific biological markers (BDNF, NSE, S100B), together with markers of inflammation and CNS alteration (IL-2, CPK, CPK-MB), and clinical evaluation were performed in two groups of patients: the ECT + antipsychotic treatment group (n=66) and the antipsychotic treatment group (n=32). Results and conclusion. In the ECT + antipsychotic treatment group, the more pronounced reduction of psychotic symptoms has been revealed compared with subjects on antipsychotic treatment as monotherapy. Patients receiving ECT showed no increase in plasma levels of inflammation and CNS alteration biomarkers (NSE, S100B, CPK, CPK-MB, IL-2). The plasma level of BDNF, capable to characterize both the efficacy and safety of antipsychotic therapy, had a more pronounced upward trend in subjects with combined electroconvulsive and antipsychotic treatment, which may indicate good tolerability and high effectiveness of ECT.

Keywords:

ECT
antipsychotic treatment
efficacy
safety
biological markers
BDNF
NSE
S100B
CPK
CPK-MB
IL-2
neuroprotection
neurodegeneration
inflammation

Authors:

Ivanov M.V.

FGBU "Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva", Sankt-Peterburg

Zubov D.S.

Bekhterev National Medical Research Center of Psychiatry and Neurology, St.-Petersburg, Russia

Close metadata

References:

  1. Wittchen HU, Jacobi F, Rehm J, Svensson GAM, Jönsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen H-C. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655-79. https://doi.org/10.1016/j.euroneuro.2011.07.018
  2. Altamura C, Fagiolini A, Galderisi S, Rocca P, Rossi A. Schizophrenia today: epidemiology, diagnosis, course and models of care. Journal of Psychopathology. 2014;20:223-243.
  3. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull. 1993;19:287-230. https://doi.org/10.1093/schbul/19.2.287
  4. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997;23(4):663-674. https://doi.org/10.1093/schbul/23.4.663
  5. Mosolov SN. Rezistentnost’ k psikhofarmakoterapii i metody ee preodoleniya. Psikhiatriya i Psikhofarmakoterapiya. 2002;4(4):132-136. (In Russ.)
  6. Solanki RK, Singh P, Munshi D. Current perspectives in the treatment of resistant schizophrenia. Indian J Psychiatry. 2009;51(4):254-260. https://doi.org/10.4103/0019-5545.58289
  7. Zervas IM, Theleritis C, Soldatos CR. Using ECT in schizophrenia: a review from a clinical perspective. World J Biol Psychiatry. 2012;13(2):96-105. https://doi.org/10.3109/15622975.2011.564653
  8. Miyamoto S, Jarskog LF, Fleischhacker WW. Schizophrenia: when clozapine fails. Curr Opin Psychiatry. 2015;28(3):243-248. https://doi.org/10.1097/yco.0000000000000159
  9. Kane J, Honigfeld G, Singer J, Meltzer H., the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796. https://doi.org/10.1001/archpsyc.1988.01800330013001
  10. Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry. 1989;46:672. https://doi.org/10.1001/archpsyc.1989.01810070098017
  11. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997;337:809-815. https://doi.org/10.1056/nejm199709183371202
  12. Englisch S, Zink M. Treatment-resistant Schizophrenia: Evidence-based Strategies. Mens Sana Monogr. 2012;10(1):20-32. https://doi.org/10.4103/0973-1229.91588
  13. Mossaheb N, Kaufmann RM. Role of aripiprazole in treatment-resistant schizophrenia. Neuropsychiatr Dis Treat. 2012;8:235-244. https://doi.org/10.2147/ndt.s13830
  14. Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. 2014;17(2):33-37. https://doi.org/10.1136/eb-2014-101813
  15. Siskind DJ, Lee M, Ravindran A, Zhang Q, Ma E, Motamarri B, Kisely S. Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Aust N Z J Psychiatry. 2018;1:4867418772351. https://doi.org/10.1177/0004867418772351
  16. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review. CADTH Technol Overv. 2012;2(3).
  17. Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, Hu Y, Maayan N, Adams C. Antipsychotic combinations for schizophrenia. The Cochrane Database of Systematic Reviews. 2017. https://doi.org/10.1002/14651858.cd009005.pub2
  18. Fink M, Taylor MA. Electroconvulsive Therapy Evidence and Challenge. JAMA. 2007;298(3):330-332. https://doi.org/10.1001/jama.298.3.330
  19. Greenhalgh J, Knight C, Hind D Beverley C, Walters S. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess. 2005;9(9):1-156. https://doi.org/10.3310/hta9090
  20. Dabrowski M, Parnowski T. Clinical analysis of safety and effectiveness of electroconvulsive therapy. Psychiatr Pol. 2012;46(3):345-360.
  21. Shimizu E, Hashimoto K, Watanabe H, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Shinoda N, Sin-ichi Okada, Masaomi Iyo. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54(1):70-75. https://doi.org/10.1016/s0006-3223(03)00181-1
  22. Li J, Ye F, Xiao W, Tang X, Sha W, Zhang X, Wang J. Increased serum brain-derived neurotrophic factor levels following electroconvulsive therapy or antipsychotic treatment in patients with schizophrenia. Eur Psychiatry. 2016;36:23-28. https://doi.org/10.1016/j.eurpsy.2016.03.005
  23. Yamamori H, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, Fujimoto M, Umeda-Yano S, Ito A, Hashimoto K, Takeda M. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett. 2013;27;556:37-41. https://doi.org/10.1016/j.neulet.2013.09.059
  24. Bilgen AE, Bozkurt ZS, Zincir S, Özdemir B, Ak M, Aydemir E, Şener I. Effects of electroconvulsive therapy on serum levels of brain-derived neurotrophic factor and nerve growth factor in treatment resistant major depression. Brain Res Bull. 2014;104:82-87. https://doi.org/10.1016/j.brainresbull.2014.04.005
  25. McFarquhar TF, Thompson J. Knowledge and attitudes regarding electroconvulsive therapy among medical students and the general public. The Journal of ECT. 2008;24 (4):244-253. https://doi.org/10.1097/yct.0b013e318168be4a
  26. Golenkov AV. Otnoshenie raznykh grupp naseleniya k elektrosudorozhnoi terapii. [Elektronnyi resurs]. Meditsinskaya psikhologiya v Rossii: elektron. nauch. zhurn. 2011;5. Data obrashcheniya: 02.07.18. URL: http://medpsy.ru (In Russ.)
  27. Baghai TC, Möller H-J. Electroconvulsive therapy and its different indications. Dialogues Clin Neurosci. 2008;10(1):105-117.
  28. Watts BV, Groft A, Bagian JP, Mills PD. An examination of mortality and other adverse events related to electroconvulsive therapy using a national adverse event report system. JECT. 2011;27(2):105-108. https://doi.org/10.1097/yct.0b013e3181f6d17f
  29. Andrade C, Arumugham SS, Thirthalli J. Adverse Effects of Electroconvulsive Therapy. Psychiatr Clin North Am. 2016;39(3):513-530. https://doi.org/10.1016/j.psc.2016.04.004
  30. Payne N, Prudic J. Electroconvulsive Therapy Part I: A Perspective on the Evolution and Current Practice of ECT. J Psychiatr Pract. 2009;15(5):346-368. https://doi.org/10.1097/01.pra.0000361277.65468.ef
  31. Hergenroeder GW, Redell JB, Moore AN, Dash PK. Biomarkers in the clinical diagnosis and management of traumatic brain injury. Mol Diagn Ther. 2008;12(6):345-358. https://doi.org/10.1007/bf03256301
  32. Mrozek S, Dumurgier J, Citerio G, Mebazaa A, Geeraerts T. Biomarkers and acute brain injuries: interest and limits. Crit Care. 2014;18(2):220. Published online 2014 Apr 24. https://doi.org/10.1186/cc13841
  33. Battista AP, Buonora JE, Rhind SG, Buonora JE, Yarnell AM, Lazarus RC, Mousseau M, Latour LL, Rizoli SB, Baker AJ, Rhind SG, Diaz-Arrastia R, Mueller GP. Multivariate analysis of traumatic brain injury: development of an assessment score. Front Neurol. 2015;6:68. https://doi.org/10.3389/fneur.2015.00068
  34. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663-671. https://doi.org/10.1016/j.biopsych.2011.04.013
  35. Annya MS, Stephen M. The Neuroimmunology of Schizophrenia. Biol Psychiatry. 2013;70(7):663-671. https://doi.org/10.9758/cpn.2013.11.3.107
  36. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 suppl):1-56.
  37. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13(2):261-276.
  38. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K.The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.